In its “skinny label” legal saga with Teva, GSK has hit back following the U.S. solicitor general’s call for the Supreme Court to rehear the years-long case. In a supplemental brief filed this week, ...
In the lengthy legal back-and-forth over the heart drug Coreg, GlaxoSmithKline has scored another victory against generic rival Teva. The decision could have far-reaching implications for the generics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback